washed, the Vitros Signal Reagent was added to the well, and the luminescence was measured (ALOKA luminometer). The IgG fraction of serum samples from the patient and from five control individuals was purified with a MAbTrap TM Kit (Amersham Biosciences), and the IgG concentration was adjusted to 4.0 g/L. The purified IgG (0.08 mL) was incubated at 4°C for 24 h with 0.08 mL of PBS alone or with T 2 , T 3 , or T 4 (Sigma; at 4570, 42, and 768 nmol/L, respectively) dissolved in PBS. Each sample was mixed vigorously with 1.2 mL of polyethylene glycol (PEG; 125 g/L), centrifuged at 2800g for 30 min, aspirated, and washed with 1.2 mL of PEG (125 g/L). After the precipitates were dissolved in 0.001 mol/L hydrochloric acid (0.04 mL) and neutralized by equal amounts of 0.001 mol/L sodium hydroxide, T 2 and T 3 were measured by the FT 3 assay and T 4 by the FT 4 assay. The concentrations of T 2 were expressed as T 3 concentrations. Each sample was analyzed in duplicate. The ability of the purified IgG to bind T 2 , T 3 , or T 4 was defined as the difference between the FT 3 or FT 4 assay result and the respective blank value and is reported as the ␦T 2 , ␦T 3 , or ␦T 4 value.
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The ratios of FT 3 and FT 4 concentrations in PEG-treated samples (6 ) to those in untreated samples were significantly lower for the patient than for 37 other patients ( 4 . The crossreactivity of the anti-T 3 antibody with T 2 in the Vitros FT3II assay was very low, whereas the patient's ␦T 2 value was evidently higher than that of 5 control individuals. We conclude that T 2 was bound to the patient's IgG.
Because anti-gelatin antibodies in the patient's serum were not recognized, we suggest that the interfering substance were antibodies to T 2 and T 3 . As the interfering antibodies did not interfere with the Elecsys FT 3 assay, the interfering antibody in the patient's serum may recognize T 2 and T 3 conjugates used in the Vitros ECi FT 3 and FT 4 assays, as reported for a labeled-antibody assay (7 ). We suggest that this interference in the Vitros ECi FT 3 and FT 4 assays arose from antibodies to T 2 , T 3 , or their conjugates. Significant interassay and interlaboratory variations in measured 25OHD values have been reported (3, 4 ) . The international Vitamin D Quality Assessment Scheme (DEQAS) monitors the performance of vitamin D assays in Ͼ100 laboratories in 18 countries (4 ) . Recently, the analysis of samples containing only 25OHD3 was reported by DEQAS to be within 7% of the target value (as determined by gas chromatography-mass spectrometry) for 5 of the 6 methods reported, with a degree of operatordependent variability. The Nichols Advantage assay, however, yielded consistently higher results, averaging ϳ31% higher than the mean of the other methods (4 ). Conversely, in 2 samples containing mostly 25OHD2, the Nichols assay consistently underestimated 25OHD compared with other assays, such as the DiaSorin RIA (4 ) .
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In Comparison of DEQAS data for the laboratories at St. George's and West Park Hospitals confirmed the reported higher values (4 ) for the Nichols (mean 25OHD concentration, 63 nmol/L) compared with the DiaSorin assay (mean 25OHD concentration, 55.5 nmol/L) for 28 paired nonstudy samples for which 25OHD was likely to be derived from vitamin D3.
The main source of 25OHD at baseline was hard to determine. In general, the source is assumed to be sunlight-derived vitamin D3, but for some patients, limited sunlight exposure, with or without reduced skin exposure, or reduced dermal capacity to synthesize vitamin D3 may mean that dietary vitamin D2 is more important (5) (6) (7) (8) (9) (10) (11) (12) . In all of the posttreatment samples, vitamin D2 was assumed to comprise the main source of measured 25OHD.
Paired 25OHD results for the Nichols Advantage and DiaSorin assays were obtained for 10 pretreatment baseline samples and for 4 samples at 6 weeks, 19 samples at 12 weeks, and 14 samples at 24 weeks after ergocalciferol treatment. The mean baseline 25OHD concentration obtained with the Nichols assay was significantly lower (24.7 nmol/L; range, 17.0 -35.0 nmol/L) than that obtained with the DiaSorin assay (34.8 nmol/L; range, 19.0 -63.0 nmol/L; P ϭ 0.041, Wilcoxon signedrank tests), as were the individual results for 8 of 10 samples. That is consistent with the predominant source of baseline 25OHD in these patients being vitamin D2, given the DEQAS data (4 ). In the posttreatment samples, an increase in 25OHD concentration compared with baseline was found with both assays, but the mean values from the DiaSorin assay were significantly higher than the Nichols values at both 12 weeks (54.7 and 30.9 nmol/L, respectively; P Ͻ0.001, Wilcoxon signed-rank test) and 24 weeks (56.4 and 34.5 nmol/L, respectively, P ϭ 0.001, Wilcoxon signed-rank test). Furthermore, in every posttreatment sample, the DiaSorin assay yielded a higher 25OHD concentration than the Nichols Advantage assay. A difference plot indicated that the disparity between the 2 assays was greater at higher concentrations (Fig. 1) .
We conclude that the Nichols assay underestimates 25OHD in patients treated with ergocalciferol and that the increasing disparity between the studied assays at higher concentrations may lead to unnecessary increases in replacement therapy and potential toxicity. 
